Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Neoplasms 67Lymphoma 55Multiple Myeloma 54Breast Neoplasms 52Neoplasm Metastasis 48Lung Neoplasms 47Prostatic Neoplasms 46Ovarian Neoplasms 39Leukemia, Myeloid, Acute 39Melanoma 37Carcinoma, Non-Small-Cell Lung 37Hematologic Neoplasms 35Colorectal Neoplasms 33Pancreatic Neoplasms 29Glioma 28Lymphoma, Non-Hodgkin 26Sarcoma 25Urinary Bladder Neoplasms 24Carcinoma, Renal Cell 24Brain Neoplasms 24Neuroblastoma 21Myelodysplastic Syndromes 21Triple Negative Breast Neoplasms 19Fallopian Tube Neoplasms 19Stomach Neoplasms 18Leukemia, Lymphocytic, Chronic, B-Cell 18Small Cell Lung Carcinoma 17Colonic Neoplasms 17Burkitt Lymphoma 17Squamous Cell Carcinoma of Head and Neck 16

Interventions

ipatasertib 1Specimen Handling 1Megestrol Acetate 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma × 90 days × Clear all
NCT05538897 2026-05-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
96 enrolled
Gynecologic

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡